journal article·2023-12-12

Investigation of the Relationship between Aptamers’ Targeting Functions and Human Plasma Proteins

Jia Liu, Zhiqiang Ren, Yang Sun, Liujun Xu, Dali Wei, Weihong Tan, Ding Ding

ACS Nano· Volume 17· Issue 23
Publisher page

Abstract

Aptamers are single-stranded DNA or RNA molecules capable of recognizing targets via specific three-dimensional structures. Taking advantage of this unique targeting function, aptamers have been extensively applied to bioanalysis and disease theranostics. However, the targeting functionality of aptamers in the physiological milieu is greatly impeded compared with their in vitro applications. To investigate the physiological factors that adversely affect the in vivo targeting ability of aptamers, we herein systematically studied the interactions between human plasma proteins and aptamers and the specific effects of plasma proteins on aptamer targeting. Microscale thermophoresis and flow cytometry analysis showed that plasma interacted with aptamers, restricting their affinity toward targeted tumor cells. Further pull-down assay and proteomic identification verified that the interactions between aptamers and plasma proteins were mainly involved in complement activation and immune response as well as showed structure-selective and sequence-specific features. Particularly, the fibronectin 1 (FN1) protein showed dramatically specific interactions with nucleolin (NCL) targeting aptamer AS1411. The competitive binding between FN1 and NCL almost deprived the AS1411 aptamer’s targeting ability in vivo . In order to maintain the targeting function in the physiological milieu, a series of optimizations were performed via the chemical modifications of AS1411 aptamer, and 3′-terminal pegylation was demonstrated to be resistant to the interaction with FN1, leading to improved tumor-targeting effects. This work emphasizes the physiological environment influences on aptamers targeting functionality and suggests that rational design and modification of aptamers to minimize the nonspecific interaction with plasma proteins might be effective to maintain aptamer functionality in future clinical uses.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Gold and Silver Nanoparticles Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, and College of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, People’s Republic of China

College of Chemistry and Materials Science, Shanghai Normal University, Shanghai 200234, People’s Republic of China

The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, People’s Republic of China

Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan 410082, People’s Republic of China

Funding

National Key Research and Development Program of China · Innovative Research Team of High-level Local University in Shanghai · Fundamental Research Funds for the Central Universities · Science and Technology Commission of Shanghai Municipality · National Natural Science Foundation of China

References (61)

Show source-provided references
1. 10.1016/j.ejpb.2015.03.01810.1016/j.ejpb.2015.03.018 ↗
2. 10.1038/nrc323610.1038/nrc3236 ↗
3. 10.1016/j.addr.2018.08.00510.1016/j.addr.2018.08.005 ↗
4. 10.1016/S0140-6736(20)30164-110.1016/S0140-6736(20)30164-1 ↗
5. 10.1146/annurev.bioeng.9.060906.15202510.1146/annurev.bioeng.9.060906.152025 ↗
6. 10.1038/nrd.2016.19910.1038/nrd.2016.199 ↗
7. 10.1002/anie.20221093510.1002/anie.202210935 ↗
8. 10.1093/nar/gkx51710.1093/nar/gkx517 ↗
9. 10.1126/sciadv.abk290110.1126/sciadv.abk2901 ↗
10. 10.1021/acs.chemrev.0c0114010.1021/acs.chemrev.0c01140 ↗
11. 10.1021/acsnano.2c1037910.1021/acsnano.2c10379 ↗
12. 10.1002/adma.20200370410.1002/adma.202003704 ↗
13. 10.1021/jacs.1c0301310.1021/jacs.1c03013 ↗
14. 10.1021/jacs.9b1075510.1021/jacs.9b10755 ↗
15. 10.1038/nrd195510.1038/nrd1955 ↗
16. 10.1007/s10637-013-0045-610.1007/s10637-013-0045-6 ↗
17. 10.3390/cancers1003008010.3390/cancers10030080 ↗
18. 10.1093/nar/gkh86210.1093/nar/gkh862 ↗
19. 10.1002/cbic.20030066310.1002/cbic.200300663 ↗
20. 10.1002/anie.20080464310.1002/anie.200804643 ↗
21. 10.1021/jacs.7b0454710.1021/jacs.7b04547 ↗
22. 10.1021/acsnano.1c0526510.1021/acsnano.1c05265 ↗
23. 10.1038/s41565-020-0759-510.1038/s41565-020-0759-5 ↗
24. 10.1021/jacs.0c0185310.1021/jacs.0c01853 ↗
25. 10.1021/acsnano.7b0800810.1021/acsnano.7b08008 ↗
26. 10.1007/s12274-018-2191-910.1007/s12274-018-2191-9 ↗
27. 10.1016/j.yexmp.2009.01.00410.1016/j.yexmp.2009.01.004 ↗
28. 10.2174/157489280866613111909595310.2174/1574892808666131119095953 ↗
29. 10.1016/j.biomaterials.2014.01.01910.1016/j.biomaterials.2014.01.019 ↗
30. 10.2174/156720181566618072410445110.2174/1567201815666180724104451 ↗
31. 10.1021/jacs.1c0085010.1021/jacs.1c00850 ↗
32. 10.1002/anie.20191603910.1002/anie.201916039 ↗
33. 10.1073/pnas.060261510310.1073/pnas.0602615103 ↗
34. 10.1039/C4CC06016D10.1039/C4CC06016D ↗
35. 10.7150/thno.1193810.7150/thno.11938 ↗
36. 10.1016/j.biomaterials.2018.03.01310.1016/j.biomaterials.2018.03.013 ↗
37. 10.7150/thno.1653210.7150/thno.16532 ↗
38. 10.1002/anie.20201562810.1002/anie.202015628 ↗
39. 10.1021/acs.analchem.1c0328710.1021/acs.analchem.1c03287 ↗
40. 10.1002/adma.20140353010.1002/adma.201403530 ↗
41. 10.1021/jacs.9b0719110.1021/jacs.9b07191 ↗
42. 10.1002/anie.20210217010.1002/anie.202102170 ↗
43. 10.1021/jacs.9b0512310.1021/jacs.9b05123 ↗
44. 10.1021/jacs.9b0372010.1021/jacs.9b03720 ↗
45. 10.1002/anie.20190380710.1002/anie.201903807 ↗
46. 10.1038/355564a010.1038/355564a0 ↗
47. 10.1242/jcs.0005910.1242/jcs.00059 ↗
48. 10.1002/anie.20210302710.1002/anie.202103027 ↗
49. 10.1002/adfm.20190008410.1002/adfm.201900084 ↗
50. 10.3390/ijms2120778110.3390/ijms21207781 ↗
51. 10.1093/nar/gkx27410.1093/nar/gkx274 ↗
52. 10.1021/jacs.9b1051010.1021/jacs.9b10510 ↗
53. 10.1038/mtna.2016.2710.1038/mtna.2016.27 ↗
54. 10.1021/acs.accounts.1c0072410.1021/acs.accounts.1c00724 ↗
55. 10.1016/j.bios.2023.11520210.1016/j.bios.2023.115202 ↗
56. 10.1002/anie.20160888010.1002/anie.201608880 ↗
57. 10.1007/s00216-016-9556-210.1007/s00216-016-9556-2 ↗
58. 10.1016/j.biotechadv.2021.10790210.1016/j.biotechadv.2021.107902 ↗
59. 10.1021/acscentsci.2c0126310.1021/acscentsci.2c01263 ↗
60. 10.1002/cpbi.310.1002/cpbi.3 ↗
61. 10.1016/j.softx.2015.06.00110.1016/j.softx.2015.06.001 ↗